Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, People's Republic of China.
Department of Respiratory and Critical Care Medicine, Shuyang Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2024 Apr 18;19:957-967. doi: 10.2147/COPD.S449521. eCollection 2024.
The Lifei Decoction (LD) is a commonly utilized Chinese medicine for the treatment of sepsis and bronchial inflammation. However, its therapeutic potential in chronic obstructive pulmonary disease (COPD) remains unknown. Therefore, the objective of this study was to investigate the therapeutic efficacy and underlying mechanism of LD in a mouse model of COPD induced by cigarette smoke (CS) combined with lipopolysaccharide (LPS).
Hematoxylin-eosin (H&E) staining was employed to observe the pathological alterations in lung tissue, while ELISA was utilized for the detection of levels of inflammatory factors in both lung tissue and bronchoalveolar lavage fluid (BALF). Additionally, Western blot analysis was conducted to assess the expression of p-NF-κB, GDF11, ZO-1, and Occludin-1 proteins. The changes in intestinal flora were evaluated using the viable bacteria count method.
The administration of LD demonstrates significant efficacy in mitigating pulmonary tissue damage in a murine model, while concurrently inhibiting the activation of the inflammatory pathway NF-κB to attenuate the levels of pro-inflammatory factors. Moreover, LD exhibits the capacity to enhance the expression of intestinal functional proteins ZO-1 and Occludin-1, thereby rectifying dysbiosis within the gut microbiota.
The LD shows great promise as a potential treatment for COPD.
来自方剂学的历肺汤（LD）是一种常用于治疗脓毒症和支气管炎症的中药。然而，它在慢性阻塞性肺疾病（COPD）中的治疗潜力尚不清楚。因此，本研究的目的是探讨 LD 在香烟烟雾（CS）联合脂多糖（LPS）诱导的 COPD 小鼠模型中的治疗效果及其潜在机制。
苏木精-伊红（H&E）染色观察肺组织的病理改变，ELISA 法检测肺组织和支气管肺泡灌洗液（BALF）中炎症因子水平。此外，还进行了 Western blot 分析，以评估 p-NF-κB、GDF11、ZO-1 和 Occludin-1 蛋白的表达。采用活菌计数法评估肠道菌群的变化。
LD 给药在减轻小鼠模型肺组织损伤方面具有显著疗效，同时抑制炎症途径 NF-κB 的激活，减轻促炎因子水平。此外，LD 还能增强肠道功能蛋白 ZO-1 和 Occludin-1 的表达，从而纠正肠道微生物群的失调。
LD 有望成为治疗 COPD 的一种潜在方法。
